Related Experiment Video
Updated: Jul 6, 2025

Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch
Published on: August 24, 2019
Historical Perspectives: Malignancy in Crohn's Disease and Ulcerative Colitis
Hannah Williams1, Randolph M Steinhagen1
1Division of Colon and Rectal Surgery, Department of Surgery, The Icahn School of Medicine at Mount Sinai, New York.
Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, increases intestinal cancer risk. This review explores IBD's history, its link to cancers, and surgical outcomes impacting oncologic results.
Area of Science:
- Gastroenterology and Oncology
- Medical History
Background:
- Crohn's disease (CD) and ulcerative colitis (UC) are forms of inflammatory bowel disease (IBD).
- IBD is associated with an increased risk of intestinal malignancies, but the mechanisms are unclear.
- Optimal screening guidelines for IBD-associated cancers are not established.
Purpose of the Study:
- To explore the historical understanding of intestinal malignancy in IBD.
- To contextualize the challenges in linking CD and UC to specific cancers.
- To review the surgical history of IBD and its impact on oncologic outcomes.
Main Methods:
- Historical review of the discovery and understanding of CD and UC.
- Examination of early research on IBD and its association with small bowel adenocarcinoma and colorectal cancer.
- Analysis of surgical histories in IBD and their oncologic implications.
Main Results:
- The historical progression of understanding IBD and its carcinogenic potential is detailed.
- Early research faced difficulties in establishing clear links between IBD subtypes and specific intestinal cancers.
- Certain surgical interventions in IBD patients have been associated with adverse oncologic outcomes.
Conclusions:
- A comprehensive historical perspective is crucial for understanding IBD-associated carcinogenesis.
- Further research is needed to elucidate mechanisms and establish optimal screening protocols.
- Understanding surgical history provides insights into managing oncologic risks in IBD patients.
Related Concept Videos
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

